Seeking Alpha

Sarepta Therapeutics (SRPT +5.5%) racks up solid gains today after the therapeutic drug...

Sarepta Therapeutics (SRPT +5.5%) racks up solid gains today after the therapeutic drug developer announced positive updated data from its Phase IIb study of eteplirsen in patients with Duchenne muscular dystrophy. Results at 74 weeks showed a continued stabilization of walking ability in eteplirsen-treated patients on a 6-minute walk test.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|